ValuEngine lowered shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) from a hold rating to a sell rating in a report released on Thursday, June 29th.
Cleveland BioLabs (NASDAQ:CBLI) traded down 3.04% during trading on Thursday, reaching $2.55. The company had a trading volume of 20,618 shares. The stock’s market capitalization is $28.76 million. The firm has a 50-day moving average of $2.99 and a 200-day moving average of $2.54. Cleveland BioLabs has a 1-year low of $1.22 and a 1-year high of $5.55.
Cleveland BioLabs (NASDAQ:CBLI) last announced its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share for the quarter. Cleveland BioLabs had a negative net margin of 111.40% and a negative return on equity of 28.45%. The business had revenue of $0.58 million for the quarter. On average, analysts anticipate that Cleveland BioLabs will post ($0.16) EPS for the current fiscal year.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.